Diversifying its portfolio to include late-phase antiviral agent
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
From material selection to cooling tower management, every small decision affects long-term equipment reliability
Dr. Jindal reflects on bridging accessibility gaps between urban and rural regions, the ethical and emotional aspects of family building, and how initiatives like adoption facilitation centers align with his lifelong mission to help couples realize the dream of parenthood
Tourmaline is now an indirect wholly owned subsidiary of Novartis
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
Subscribe To Our Newsletter & Stay Updated